Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
Aprea Therapeutics (NASDAQ: APRE) provided an update on its patent portfolio for DNA Damage Response (DDR) cancer therapeutics. The company's ATR inhibitor program is protected by four granted U.S. patents, one pending U.S. application, and one provisional application, along with 19 granted non-U.S. patents and 16 pending non-U.S. applications. These patents expire between 2035-2037, with pending applications potentially extending exclusivity to 2044.
The company's lead ATR inhibitor, ATRN-119, is being evaluated in the ABOYA-119 clinical trial for advanced solid tumors. Additionally, Aprea's WEE1 kinase inhibitor program includes one pending U.S. patent application and 12 pending non-U.S. applications, set to expire in 2043 if granted. The lead WEE1 inhibitor, APR-1051, is currently in Phase 1 clinical trials (ACESOT-1051) for advanced/metastatic solid tumors.
Aprea Therapeutics (NASDAQ: APRE) ha fornito un aggiornamento sul suo portafoglio brevetti per i terapeutici oncologici basati sulla Risposta al Danno del DNA (DDR). Il programma di inibitori di ATR della società è protetto da quattro brevetti statunitensi concessi, una domanda statunitense in sospeso e una domanda provvisoria, insieme a 19 brevetti non statunitensi concessi e 16 domande non statunitensi in sospeso. Questi brevetti scadranno tra il 2035 e il 2037, con le domande in sospeso che potrebbero estendere l'esclusività fino al 2044.
Il principale inibitore di ATR della società, ATRN-119, è in fase di valutazione nello studio clinico ABOYA-119 per tumori solidi avanzati. Inoltre, il programma di inibitori della chinasi WEE1 di Aprea include una domanda di brevetto statunitense in sospeso e 12 domande non statunitensi in sospeso, che scadranno nel 2043 se concesse. Il principale inibitore di WEE1, APR-1051, è attualmente in fase di sperimentazione clinica di Fase 1 (ACESOT-1051) per tumori solidi avanzati/metastatici.
Aprea Therapeutics (NASDAQ: APRE) proporcionó una actualización sobre su cartera de patentes para terapias contra el cáncer basadas en la Respuesta al Daño del ADN (DDR). El programa de inhibidores de ATR de la compañía está protegido por cuatro patentes estadounidenses otorgadas, una solicitud estadounidense pendiente y una solicitud provisional, además de 19 patentes no estadounidenses otorgadas y 16 solicitudes no estadounidenses pendientes. Estas patentes expiran entre 2035 y 2037, con las solicitudes pendientes que podrían extender la exclusividad hasta 2044.
El principal inhibidor de ATR de la compañía, ATRN-119, se está evaluando en el ensayo clínico ABOYA-119 para tumores sólidos avanzados. Además, el programa de inhibidores de quinasa WEE1 de Aprea incluye una solicitud de patente estadounidense pendiente y 12 solicitudes no estadounidenses pendientes, que están programadas para expirar en 2043 si se otorgan. El principal inhibidor de WEE1, APR-1051, se encuentra actualmente en ensayos clínicos de Fase 1 (ACESOT-1051) para tumores sólidos avanzados/metastáticos.
Aprea Therapeutics (NASDAQ: APRE)는 DNA 손상 반응(DDR) 암 치료를 위한 특허 포트폴리오에 대한 업데이트를 제공했습니다. 회사의 ATR 억제제 프로그램은 4개의 미국 특허와 1개의 보류 중인 미국 신청서, 1개의 임시 신청서, 그리고 19개의 비미국 특허와 16개의 비미국 신청서로 보호되고 있습니다. 이 특허는 2035년에서 2037년 사이에 만료되며, 보류 중인 신청서는 2044년까지 배타성을 연장할 가능성이 있습니다.
회사의 주요 ATR 억제제 ATRN-119는 진행성 고형 종양에 대한 ABOYA-119 임상 시험에서 평가되고 있습니다. 또한 Aprea의 WEE1 키나제 억제제 프로그램은 1개의 보류 중인 미국 특허 신청서와 12개의 보류 중인 비미국 신청서를 포함하며, 이는 승인될 경우 2043년에 만료될 예정입니다. 주요 WEE1 억제제인 APR-1051는 현재 진행성/전이성 고형 종양에 대한 1상 임상 시험(ACESOT-1051)에 있습니다.
Aprea Therapeutics (NASDAQ: APRE) a fourni une mise à jour sur son portefeuille de brevets pour les thérapies anticancéreuses basées sur la Réponse aux Dommages de l'ADN (DDR). Le programme d'inhibiteurs d'ATR de la société est protégé par quatre brevets américains accordés, une demande américaine en attente et une demande provisoire, ainsi que 19 brevets non américains accordés et 16 demandes non américaines en attente. Ces brevets expirent entre 2035 et 2037, les demandes en attente pouvant potentiellement prolonger l'exclusivité jusqu'en 2044.
L'inhibiteur principal d'ATR de la société, ATRN-119, est évalué dans l'essai clinique ABOYA-119 pour les tumeurs solides avancées. De plus, le programme d'inhibiteurs de la kinase WEE1 d'Aprea comprend une demande de brevet américain en attente et 12 demandes non américaines en attente, qui devraient expirer en 2043 si elles sont accordées. L'inhibiteur principal de WEE1, APR-1051, est actuellement en phase 1 des essais cliniques (ACESOT-1051) pour les tumeurs solides avancées/métastatiques.
Aprea Therapeutics (NASDAQ: APRE) hat ein Update zu seinem Patentportfolio für DNA-Schadenreaktion (DDR) Krebsmedikamente veröffentlicht. Das ATR-Inhibitoren-Programm des Unternehmens ist durch vier erteilte US-Patente, einen anhängigen US-Antrag und einen vorläufigen Antrag sowie 19 erteilte Nicht-US-Patente und 16 anhängige Nicht-US-Anträge geschützt. Diese Patente laufen zwischen 2035 und 2037 ab, wobei anhängige Anträge die Exklusivität möglicherweise bis 2044 verlängern könnten.
Der Haupt-ATR-Inhibitor des Unternehmens, ATRN-119, wird in der klinischen Studie ABOYA-119 für fortgeschrittene solide Tumoren bewertet. Darüber hinaus umfasst Apreas WEE1-Kinase-Inhibitor-Programm einen anhängigen US-Patent-Antrag und 12 anhängige Nicht-US-Anträge, die, falls genehmigt, 2043 ablaufen. Der führende WEE1-Inhibitor APR-1051 befindet sich derzeit in Phase-1-Studien (ACESOT-1051) für fortgeschrittene/metastatische solide Tumoren.
- Strong patent protection with 23 granted patents globally
- Patent protection extends until 2037, with potential extension to 2044
- Two clinical-stage programs: ATRN-119 and APR-1051
- Additional regulatory exclusivity potential of up to 5 years
- WEE1 inhibitor patents still pending, not yet granted
- Some patent applications may not be granted, risking future market exclusivity
Insights
The strategic evolution of Aprea's intellectual property portfolio represents a significant strengthening of their competitive position in the oncology space. The patent estate for their ATR inhibitor program is particularly robust, with protection extending potentially to 2044, providing important market exclusivity during the prime commercial years of ATRN-119.
The multi-layered patent strategy is noteworthy: First, the granted patents through 2037 provide immediate protection for core technology. Second, pending applications could extend protection to 2044 and third, potential regulatory exclusivity adds up to 5 more years. This comprehensive approach effectively creates a 25-year protection window, which is exceptional in the pharmaceutical industry.
For investors, this IP portfolio offers three key advantages:
- Strong barriers to entry against potential competitors, particularly valuable in the competitive DDR therapeutics space
- Multiple layers of protection across different jurisdictions, reducing risk of patent challenges
- Extended market exclusivity timeline that aligns with typical drug commercialization cycles
The parallel protection of both ATR and WEE1 inhibitor programs is strategically crucial, as it safeguards multiple approaches to targeting DNA damage response pathways. This diversification not only protects individual assets but also potential combination therapies, which are increasingly important in oncology treatment paradigms.
DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio.
“Our strong patent portfolio reflects our commitment to innovation and leadership in the field of DNA Damage Response therapeutics,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “Intellectual property is an essential component of Aprea’s strategy, enabling us to advance first in class and best in class oncology treatments while protecting the value of our assets. Our commitment to securing global intellectual property rights underscores our long-term vision to develop and commercialize breakthrough therapies for difficult to treat cancers.”
Aprea’s ATR inhibitor program is protected by a strong patent estate, including four granted U.S. patents, one pending U.S. application, and one pending provisional application. There are 19 granted non-U.S. patents and 16 pending non-U.S. patent applications. The granted patents will expire 2035-2037 and the pending applications, if granted, could extend exclusivity into 2044. Additional regulatory exclusivities up to five years may also be available. This portfolio comprehensively covers the program’s proprietary compounds, pharmaceutical compositions, and methods of use. The Company’s lead ATR inhibitor, ATRN-119, is currently being evaluated in the ABOYA-119 clinical trial as monotherapy in patients with advanced solid tumors having at least one mutation in a defined panel of DNA damage response (DDR)-related genes.
The intellectual property covering Aprea’s WEE1 kinase inhibitor program includes one pending U.S. patent application and 12 pending non-U.S. patent applications. The WEE1 family of applications, if granted, will expire in 2043, not including any regulatory exclusivities that may be awarded. The WEE1-portfolio covers key aspects of the program, including proprietary compounds, pharmaceutical compositions, and methods of use. The Company’s lead WEE1 inhibitor, APR-1051, is currently being evaluated in the ACESOT-1051 Phase 1 clinical trial in advanced/metastatic solid tumors harboring certain cancer-associated gene alterations.
About Aprea
Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
Investor and Media Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
FAQ
When do Aprea Therapeutics' (APRE) ATR inhibitor patents expire?
How many patents does Aprea Therapeutics (APRE) have for its ATR inhibitor program?
What clinical trials is Aprea Therapeutics (APRE) currently conducting?
When will Aprea Therapeutics' (APRE) WEE1 inhibitor patents expire?
